Botuinum toxin

Phase 2Small molecule

UUniversity Hospital of North Norway

Botuinum toxin is one of 4 small molecule programs targeting Frostbite. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FrostbiteActive, not recruiting

FrostbitePhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Frostbite

#DrugCompanyPhaseTrials

Dalvance

AbbVie

Approved

1 2

Aurlumyn

BBTG International Inc.

Preclinical

1 3

IC-Green

CCHX Technologies Inc.

Preclinical

—4

Botuinum toxin

UUniversity Hospital of North Norway

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Frostbite1 trial

Treatment of Frostbite Sequelae With Botulinum Toxin A

Withdrawn·UUniversity Hospital of North Norway·Phase 2·NCT06460194

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Botuinum toxin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Botuinum toxin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Botuinum toxin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital of North Norway company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital of North Norway

Botuinum toxin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Frostbite1 trial

References

Drug Info

Quick Facts

Related News